LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New RNA-Based Breath Test to Detect COVID-19 More Predictive of Lower Respiratory Tract Involvement

By LabMedica International staff writers
Posted on 21 Feb 2022
Print article
Image: New RNA-Based Breath Test to Detect COVID-19 More Predictive of Lower Respiratory Tract Involvement (Photo courtesy of William G. Fairbrother)
Image: New RNA-Based Breath Test to Detect COVID-19 More Predictive of Lower Respiratory Tract Involvement (Photo courtesy of William G. Fairbrother)

Researchers have developed a unique method for detecting SARS-CoV-2 in breath samples using viral RNA detection.

A team of researchers at Brown University (Providence, RI, USA) has created a breathalyzer device that reverse-transcribes RNA from airborne virus particles into DNA, which can then be tested for COVID-19 via a common PCR test. The device, dubbed the Bubbler, uses an enzymatic reaction mixture to detect viral RNA and convert it to DNA, where it can be measured using a PCR instrument. The Bubbler can also barcode that DNA, allowing a sample to be linked directly to the patient it came from and be used for sequencing.

The Bubbler is a glass tube with a glass pipette into which patients exhale. The tube is filled with a reverse transcription reaction mixture and cold mineral oil. The name of the device comes from the bubbling sound that occurs when the patient exhales into the device. In the study, 70 patients were screened and samples from three points in the respiratory tract were tested: Saliva obtained from tongue scrapes in the mouth and samples of 15 seconds of exhaled breath collected in the Bubbler were compared to a conventional nasopharyngeal swab PCR test.

The study determined that SARS-CoV-2 can be readily detected in the breath and is more predictive of lower respiratory tract involvement. Viral RNA is more enriched in the breath relative to oral samples, while oral samples include cells involved with SARS-CoV-2 replication that breath samples do not. This suggests the viral signal detected in the Bubbler comes from active viral particles. Tests for COVID-19 usually use samples collected from the upper respiratory tract by saliva or nasopharyngeal swab. Positive samples contain active virus, but viral load in the upper respiratory tract is not correlated with symptoms in the lower respiratory tract, such as pneumonia.

Virus detection by the Bubbler is similar to a hospital-swab PCR test. However, because swab tests detect viral RNA fragments in cells that persist in previously infected cells, PCR tests can return a positive result for months after infection. By contrast, the Bubbler detects airborne viral particles and is a better measure of risk of contagion. It can also be adapted for environmental sampling in hospitals, transportation hubs and closed environments like offices, ships and planes. The barcode returns a viral sequence that also supports strain identification, which may prove useful as more information is learned about transmissibility and possible strain-specific treatment decisions. It can also be used for simultaneous batches of pooled samples, provides additional information such as viral load and strain identity, and eliminates the need for stabilizing a sample, potentially allowing the assay to be performed at home.

The investigators also demonstrated how the Bubbler might be adapted to detect virus in airborne samples. To model the movement of droplets exhaled in human breath, three unique nucleic acid samples were added to three personal humidifiers at different locations at varied distances from the Bubbler in a room with high airflow and a room with low airflow. Although a detailed exploration of this application was beyond the scope of the study, the results demonstrate the potential to use aerosolized nucleic acids to quantitatively map airflow in indoor spaces, and to detect SARS-CoV-2 in the air.

“The Bubbler is more likely to be a better indicator of current infection than nasopharyngeal swabs,” said lead investigator William G. Fairbrother, a professor in the Department of Molecular Biology, Cell Biology and Biochemistry at Brown. “Involvement of the lower respiratory tract is often a precursor to severe COVID-19, so there is an argument for a more direct sampling focused on exhaled breath.”

Related Links:
Brown University 

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.